Printer Friendly

VESTAR FILES NEW DRUG APPLICATION FOR DAUNOXOME (R) AS TREATMENT FOR KAPOSI'S SARCOMA PATIENTS

 SAN DIMAS, Calif., Feb. 24 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that it has filed a New Drug Application (NDA) with the Food and Drug Administration for DaunoXome (R), Vestar's proprietary liposomal formulation of the anthracycline anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma (KS).
 KS is the most common of cancers that afflict AIDS patients, causing a wide spectrum of serious and debilitating symptoms. It is characterized by lesions of the skin, mucous membranes and lymph nodes, and often progresses rapidly to internal organs, including the lungs and gastrointestinal tract. This disease affects an estimated 15 percent or more of AIDS patients.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds. Since 1989, Vestar has been marketing in Europe AmBisome (R), a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome (R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is Vestar's second major product.
 -0- 2/24/93
 /CONTACT: Michael E. Hart, chief financial officer of Vestar, 909-394-4119, or Marcia A. Kean, executive VP of Feinstein Partners, 617-577-8110, for Vestar/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU: PDT

KD -- NY001 -- 9727 02/24/93 07:57 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 24, 1993
Words:231
Previous Article:HEY KIDS, THE EASTER BUNNY SENDS PERSONAL GREETINGS THIS SPRING WITH A LITTLE HELP FROM CURRENT, INC.
Next Article:WALLACE COMPUTER SERVICES, INC. ANNOUNCES SECOND QUARTER RESULTS
Topics:


Related Articles
CLINICAL DATA CONFIRM HIGH DEGREE OF SAFETY AND EFFICACY FOR VESTAR'S DAUNOXOME(TM) IN KAPOSI'S SARCOMA
ANIMAL DATA ON VESTAR'S DAUNOXOME SUPPORT EMERGING CLINICAL PROFILE AGAINST CANCER
CLINICAL RESULTS ON VESTAR'S DAUNOXOME IN AIDS-RELATED KAPOSI'S SARCOMA PRESENTED AT AIDS CONFERENCE
VESTAR TO PROVIDE DAUNOXOME TO PATIENTS WITH AIDS-RELATED KARPOSI'S SARCOMA ON A LIMITED BASIS
FUJISAWA USA FILES IND APPLICATION FOR VESTAR'S AMBISOME(R)
VESTAR FILES PATENT INFRINGEMENT LAWSUIT IN UNITED KINGDOM AGAINST LIPOSOME TECHNOLOGY, INC.
VESTAR'S MIKASOME ACTIVE AGAINST DRUG-RESISTANT TUBERCULOSIS; ONE OF FOUR NEW PRODUCTS HEADED TO CLINIC, VESTAR ANNOUNCES
VESTAR'S DAUNOXOME DESIGNATED ORPHAN DRUG FOR KAPOSI'S SARCOMA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters